Equities

Avalo Therapeutics Inc

Avalo Therapeutics Inc

Actions
  • Price (EUR)8.36
  • Today's Change0.04 / 0.48%
  • Shares traded--
  • 1 Year change-64.99%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 19:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7.421355
Total Receivables, Net0.141.924.80
Total Inventory00.020.04
Prepaid expenses0.841.292.37
Other current assets, total0.000.020.05
Total current assets8.401662
Property, plant & equipment, net1.972.412.70
Goodwill, net111414
Intangibles, net--00.04
Long term investments------
Note receivable - long term------
Other long term assets--01.00
Total assets213380
LIABILITIES
Accounts payable0.452.883.37
Accrued expenses4.171316
Notes payable/short-term debt000
Current portion long-term debt/capital leases05.93--
Other current liabilities, total00.600.38
Total current liabilities4.622220
Total long term debt01333
Total debt01933
Deferred income tax0.160.140.11
Minority interest------
Other liabilities, total8.928.544.30
Total liabilities144457
SHAREHOLDERS EQUITY
Common stock0.000.010.11
Additional paid-in capital342293285
Retained earnings (accumulated deficit)(335)(304)(262)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity7.30(11)23
Total liabilities & shareholders' equity213380
Total common shares outstanding0.800.040.04
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.